JP2024511208A5 - - Google Patents

Info

Publication number
JP2024511208A5
JP2024511208A5 JP2023559684A JP2023559684A JP2024511208A5 JP 2024511208 A5 JP2024511208 A5 JP 2024511208A5 JP 2023559684 A JP2023559684 A JP 2023559684A JP 2023559684 A JP2023559684 A JP 2023559684A JP 2024511208 A5 JP2024511208 A5 JP 2024511208A5
Authority
JP
Japan
Prior art keywords
approximately
weight
basis
maximum
weight basis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/en
Publication of JP2024511208A publication Critical patent/JP2024511208A/ja
Publication of JP2024511208A5 publication Critical patent/JP2024511208A5/ja
Pending legal-status Critical Current

Links

JP2023559684A 2021-03-27 2022-03-28 治療薬のバイオアベイラビリティを改善した組成物 Pending JP2024511208A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166995P 2021-03-27 2021-03-27
US63/166,995 2021-03-27
US202263269330P 2022-03-14 2022-03-14
US63/269,330 2022-03-14
PCT/EP2022/058180 WO2022207580A2 (en) 2021-03-27 2022-03-28 Compositions having improved bioavailability of therapeutics

Publications (2)

Publication Number Publication Date
JP2024511208A JP2024511208A (ja) 2024-03-12
JP2024511208A5 true JP2024511208A5 (cg-RX-API-DMAC10.html) 2025-04-04

Family

ID=81386993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559684A Pending JP2024511208A (ja) 2021-03-27 2022-03-28 治療薬のバイオアベイラビリティを改善した組成物

Country Status (8)

Country Link
US (2) US12678502B2 (cg-RX-API-DMAC10.html)
EP (1) EP4312978A2 (cg-RX-API-DMAC10.html)
JP (1) JP2024511208A (cg-RX-API-DMAC10.html)
KR (1) KR20240021751A (cg-RX-API-DMAC10.html)
AU (1) AU2022248850A1 (cg-RX-API-DMAC10.html)
CA (1) CA3212583A1 (cg-RX-API-DMAC10.html)
IL (1) IL306029A (cg-RX-API-DMAC10.html)
WO (1) WO2022207580A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895537B2 (en) * 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
AU2022248850A1 (en) 2021-03-27 2023-11-09 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
WO2023174941A1 (en) * 2022-03-14 2023-09-21 TRx Biosciences Limited Fibrate compositions for treating inflammation and neuroinflammation
WO2024123935A2 (en) * 2022-12-07 2024-06-13 Freedom Biosciences, Inc. Treatment or prevention of depressive disorders through combination therapy
WO2025093572A1 (en) * 2023-10-29 2025-05-08 TRx Biosciences Limited Solid dispersion compositions and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2091152C (en) * 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6762203B2 (en) * 1999-08-03 2004-07-13 Kao Corporation Oil composition
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP3769203B2 (ja) * 2001-03-26 2006-04-19 花王株式会社 ペットフード又は飼料
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
WO2006017692A2 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
JP5758630B2 (ja) 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
ES2423793T3 (es) 2008-05-26 2013-09-24 Genfit Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias
CN101366697A (zh) * 2008-08-14 2009-02-18 沈阳万爱普利德医药科技有限公司 一种新的包含紫杉醇类物质的注射用纳米脂质载体及其制备方法
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
CN101507707B (zh) 2009-04-08 2011-01-19 邓菊娟 一种盐酸法舒地尔脂微球制剂及其制备方法
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
WO2012104655A2 (en) 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
JP2014518609A (ja) 2011-03-03 2014-08-07 テルサス ファーマシューティカルズ リミテッド ライアビリティ カンパニー C16:1n7−パルミトレアートを含む組成物および方法
CN102813639B (zh) 2011-06-08 2014-04-30 中国疾病预防控制中心寄生虫病预防控制所 甲苯达唑软胶囊剂
WO2013049749A2 (en) * 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
US9073944B2 (en) 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
MX377877B (es) 2013-01-14 2025-03-11 Infirst Healthcare Ltd Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
JP6474732B2 (ja) 2013-01-14 2019-02-27 インファースト ヘルスケア リミテッド 激痛治療用組成物と方法
CN105120900A (zh) 2013-02-04 2015-12-02 因佛斯特医疗有限公司 用于治疗慢性炎症和炎性疾病的组合物及方法
US20160000714A1 (en) * 2013-03-06 2016-01-07 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
AU2014360537B2 (en) 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
CN108025078A (zh) 2015-08-07 2018-05-11 因佛斯特医疗有限公司 用于nsaid的固体溶液组合物
ES2975417T3 (es) 2017-03-03 2024-07-05 Inspirna Inc Formulaciones con estabilidad mejorada
AU2019231699B2 (en) 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
WO2020079706A1 (en) 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
WO2020217235A1 (en) 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
WO2020225395A1 (en) * 2019-05-07 2020-11-12 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
AU2022248850A1 (en) 2021-03-27 2023-11-09 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
CN113546045B (zh) 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用

Similar Documents

Publication Publication Date Title
JP2025509680A5 (cg-RX-API-DMAC10.html)
JP4790123B2 (ja) 胆汁酸を有する透明水溶液型製剤の調剤
JP6474732B2 (ja) 激痛治療用組成物と方法
PT2429317T (pt) Composições ricas em ácidos gordos ómega-3 com um teor baixo de ácido fitânico
BRPI0013939B1 (pt) Pharmaceutical composition for controlling or avoiding obesity, process for preparing and using the same
JPH0147445B2 (cg-RX-API-DMAC10.html)
KR100533460B1 (ko) 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
CN103957888A (zh) 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
JP2020530464A5 (cg-RX-API-DMAC10.html)
NO343582B1 (no) Oral medikamentformulering omfattende ospemifen
EP0246294A1 (en) USE OF A HYDROPHOBIC SUBSTANCE TO PREPARE AN ENTERIC PREPARATION FOR TREATING OBESITY, AND ENTERIC PREPARATION.
WO2014158256A1 (en) Omega-3 pentaenoic acid compositions and methods of use
WO2001005406A1 (fr) Preparations de glycyrrhizine pour absorption par voie transmuqueuse
AU2020361994A1 (en) Liquid crystalline structure-forming omega-3-fatty acid composition
CN101304738A (zh) 非培米芬的制剂
EP3232798A1 (en) Enhanced omega-3 formulations
JPS61224962A (ja) 昆布エキス含有カプセル
WO1985004804A1 (fr) Agent cholagogique/cholelithotriptique
DE19645044A1 (de) Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
JP2001513493A (ja) 経鼻投与用組成物
JP4794148B2 (ja) ネフローゼ症候群治療剤
JP4452970B2 (ja) ジクロフェナクナトリウム経口製剤
PT1311260E (pt) Utilização de inibidores de lipase para o tratamento da dispepsia
US20240316073A1 (en) Cannabidiolic acid esters for treating prader-willi syndrome
JP2025508890A5 (cg-RX-API-DMAC10.html)